The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.
Am J Manag Care
; 30(8): e223-e225, 2024 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-39146478
ABSTRACT
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
United States Food and Drug Administration
/
Aprovação de Drogas
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article